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Abstract 
Our objective was to determine the factors affecting the 
prognosis in patients with major salivary gland malignancy 
presenting to Aga Khan University Hospital in Karachi. 
Retrospective cohort study was carried out at our center 
on patients diagnosed and treated for salivary gland 
cancers. Presentation and treatment offered was reviewed 
from medical charts. Telephonic interviews were 
conducted to assess the survival of patients who were lost 
to follow-up. Log rank test was used to compare the mean 
survival times. A total of 36 patients were included in the 
study. The mean age was 45.1 +/- 14.6 years. Majority were 
male 21 (58.3%). The most common malignancy was 
mucoepidermoid carcinoma (36.1%) followed by adenoid 
cystic carcinoma (22.2%). Node positivity, grade of tumor, 
radiotherapy and chemotherapy were a significant 
indication of survival times on log rank test. 




Salivary gland malignancies are a heterogeneous group of 
tumours that have varying biological behaviours. These 
tumours comprise 3-10% of all head and neck 
malignancies.1 The global annual incidence varies between 
0.05 – 2/100,000.1 The incidence of major salivary gland 
malignancies increases with age; the overall incidence is 
rare for below 40 years of age.1 Males are more often 
affected than females.1 Malignancy of salivary gland is 
uncommon and therefore there are few prospective studies 
on the subject.2 Exact cause of Salivary gland neoplasms is 
unknown.3 Low intake of cholesterol has shown to have a 
protective role.4 Intake of dark yellow vegetables and liver 
also showed to reduce risk of salivary gland neoplasms.5 
There is a knowledge gap regarding the behaviour and 
survival of patients suffering from salivary gland 
malignancy in our population. Studies have shown 
difference in survival with grade of tumour6 and type of 
tumour.7,8 Advanced radiation therapy techniques like 
IMRT have shown survival benefits.9,10 We hypothesized 
that the prognostic factors differ in our cohort of patients 
than those reported in the West. 
Material Methods and Results 
A retrospective cohort study was conducted at Aga Khan 
University Hospital Karachi Pakistan. Prior to the 
commencement of our survey, approval was obtained from 
the institutional ethical review committee. All the patients 
who were treated for a salivary gland malignancy from 
January 1, 2005 to December 31, 2015 were reviewed for 
the study. The data was obtained from a prospectively 
maintained database. The data were collected by a 
qualified and trained data collector. Patient demographics, 
tumour and treatment related variables were obtained 
from medical charts using a proforma. Information on the 
overall survival was obtained by telephonic interview of the 
patients who were lost to follow up. Patients that had a 
salivary gland malignancy on final histopathology and who 
were over the age of 18 years were included for the 
analysis. Those with benign lesions; those who received 
prior treatment before presentation at our institute, and 
those with distant metastasis at the time of arrival were 
excluded. Patients with incomplete records, and those who 
did not complete their treatment were also excluded from 
the study.  
The data was analyzed using STATA version 12. Continuous 
variables are reported with mean ± standard deviation and 
categorical variables are reported with frequencies and 
percentages. Survival analysis was done using cox 
proportional hazard ratio and Kaplan Meier curves drawn 
to graphically illustrate the survival proportion. 
Schoenfeld's global test was used to assess if the data 
fulfilled the assumption of proportionality. A total of 36 
patients matched the eligibility criteria. The mean age of 
the patients was 45.08 ± 14.57 years and the majority were 
male 21 (58.3%). The most common site of malignancy was 
the parotid gland 31 (58.3%). The fine needle aspiration 
cytology revealed malignancy in 12 cases (33.3%). Final 
histopathology reported mucoepidermoid carcinoma in 13 
cases (36.1%) followed by adenoid cystic carcinoma in 8 
cases (22.2%); 5 cases of Acinic cell carcinoma (13.9%), 3 of 
squamous cell carcinoma (8.3%) and a small proportion of 
other malignancies were also reported. Table-1. 
Majority of the cases 19 (52.8%) were reported as high 
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grade on final histopathology while 12 cases as low or 
intermediate grade (47.2%). Neck dissection was carried 
out on 21 cases (58.3%) due to clinical or radiological 
suspicion of malignancy, 12 cases (57.1%) had at least one 
positive lymph node on final histopathology. We had 31 
cases of parotid gland and 5 cases of submandibular gland 
malignancy. Among those with parotid gland involvement, 
19 cases (52.8%) underwent parotidectomy along with 
neck dissection and 11 cases (30.7%) only underwent 
parotidectomy. Majority of the patients 21 (58.3%) received 
adjuvant radiotherapy whereas only 3 cases received 
chemoradiotherapy.  
The mean survival time of the patients are presented in 
Table 2. Log rank test was used to test the significance of 
survival time in stratifying the variables. The significant 
prognostic factors were Node positivity (p=0.001), 
radiotherapy (p=0.06) and chemotherapy (p=0.03). 
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Figure-1: Kaplan Meier curves showing the mean survival time (months) of patients 
stratified on grade of tumor.
Figure-2: Kaplan Meier curves showing the mean survival time of patients in months 
stratified on node positivity.
Table-1: Patient demographics, tumour and treatment variables with respect to  
survival status. 
Variable Outcome status 
 Alive Event 
 (Dead) 
Mean ± SD (Continuous) 
Frequencies n (%) (Categorical) 
Age 45.1 ± 14.6 
Gender Male 16 (76.19) 5 (23.81) 
Female 12 (80) 3 (20) 
Site Parotid gland 25 (80.65) 6 (19.35) 
Submandibular gland 3   (60) 2 (40) 
FNAC Positive 9   (75) 3 (25) 
Negative 19 (71.17) 5 (20.83) 
Final histopathology Mucoepidermoid 10 (76.92) 3 (23.08) 
Adenoid cystic 6   (75) 2 (25) 
Acinic cell 5   (100) 0 
Squamous cell carcinoma 1   (33.33) 2 (66.67) 
Lymphoepithelial  
carcinoma 1   (100) 0 
Salivary duct carcinoma  
Adenocarcinoma 0 1 (100) 
Carcinoma ex pleomorphic 1 (100) 0 
Poorly differentiated ca 2 (100) 0 
Tumor Grade Low/Intermediate 17 (100) 0 
High 11 (57.89) 8 (42.11) 
Neck dissection Yes 13 (61.90) 8 (38.10) 
No 15 (100) 0 
Node positivity Yes 5 (41.67) 7 (58.33) 
No 23 (95.83) 1 (4.17) 
Surgery Parotidectomy 11 (100) 0 
Parotidectomy + Neck 13 (68.42) 6 (31.58) 
Dissection  
Submandibular gland excision 3   (100) 0 
Submandibular gland excision 1  (33.33) 2 (66.67) 
+ Neck dissection 
Radiotherapy Yes 14 (66.67) 7 (33.33) 
No 14 (93.33) 1 (6.67) 
Chemotherapy Yes 1 (33.33) 2 (66.67) 
No 27 (81.82) 6 (18.18) 
Table-2: Mean survival time (months) and log rank test. 
Variable Category Mean survival time  Log rank test  
(Months) (p-value) 
Gender Male 209.59 0.36 
Female 122.79 
Site Parotid gland 157.28 0.35 
Submandibular gland 55.4 
FNAC Positive 105.56 0.21 
Negative 155.76 
Node positivity Yes 54.52 0.001 
No 100.13* 
Radiotherapy Yes 66.31* 0.06 
No 97.73* 
Chemotherapy Yes 43.5 0.03 
No 83.76* 
*Restricted Mean (last observation censored)
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Due to sparse data, further analysis (univariate and 
multivariable analysis) was not done. 
Kaplan Meier curves graphically show the mean survival 
time of patients stratified by grade of tumour and node 
positivity. (Figure 1,2) 
Conclusion 
Grade of the tumour, positive lymph node status and 
adjuvant therapy are the prognostic factors that 
significantly alter the survival time in our cohort of patients 
with salivary gland cancer. Patients with high grade tumour 
and positive neck nodes require aggressive adjuvant 
treatment and close follow-ups. 
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